Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avastin filed for lung cancer in Japan

This article was originally published in Scrip

Executive Summary

Chugai (Roche) has filed a submission in Japan for the approval of Avastin (bevacizumab) for the additional indication of non-small cell lung cancer. The application is for the first-line treatment of non-squamous advanced or recurrent disease in combination with standard platinum-based therapy, as approved in the US in 2006 and Europe last year. The VEGF-targeting antibody was approved for non-resectable advanced or recurrent colorectal cancer in Japan in April 2007. Chugai noted that the incidence of lung cancer in the country was forecast to rise to around 99,000 cases in 2010, and that NSCLC was already the leading cause of local cancer deaths.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC032086

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel